Sweet flowers are slow, and weeds make haste: leveraging methodology from research on tobacco, alcohol, and opioid analgesics to make rapid and policy-relevant advances in cannabis science.
Sweet flowers are slow, and weeds make haste: leveraging methodology from research on tobacco, alcohol, and opioid analgesics to make rapid and policy-relevant advances in cannabis science.
复制标题
甜花很慢，杂草匆忙：从烟草，酒精和阿片类镇痛药的研究中利用方法，以在大麻科学方面取得快速且与政策相关的进步。
DOI：
10.1080/09540261.2018.1465400
复制
发表时间：
2018-06
期刊：
影响因子：
--
通讯作者：
Peters EN
中科院分区：
文献类型：
--
作者：
Herrmann ES;Jarvis BP;Sparks AC;Cohn AM;Koszowski B;Rosenberry ZR;Coleman-Cowger VH;Pickworth WB;Peters EN
医用和娱乐用大麻的合法化先于科学。目前的证据基础在确定大麻产品是否符合现代医学固有的安全性、有效性和质量标准以及为大麻作为合法麻醉剂的监管提供信息方面作用不大。通过大麻改革的个别司法管辖区可能没有足够的资源来支持为监管行动提供信息所需的新科学研究水平；这可能会使快速增长的数十亿美元的大麻产业难以受到控制。此外，目前缺乏对大麻的循证监管，与导致烟草和处方阿片类药物流行的气候相似，这表明继续疏忽可能会导致负面的公共卫生后果。然而，通过对这些化合物的研究而形成的翻译方法学框架可能会促进大麻科学的快速进展，与管制知识差距密切相关。本审查强调了在这些领域以及酒精管制方面的具体进展，这些进展对于宣传与政策有关的大麻科学至关重要，并就循证监管政策提出了一些建议。由此取得的进展可能直接影响医用和合法娱乐用毒品框架中对大麻的管制，以及与大麻有关的新的公共卫生倡议。
The legalization of medical and recreational cannabis use has occurred ahead of science. The current evidence base has poor utility for determining if cannabis products can meet the standards of safety, efficacy, and quality intrinsic to modern medicine, and for informing regulation of cannabis as a legal intoxicant. Individual jurisdictions that pass cannabis reforms may not have adequate resources to support the level of new scientific research needed to inform regulatory actions; this could make it difficult to keep a rapidly growing multi-billion-dollar cannabis industry in check. Further, the present lack of evidence-based regulatory oversight for cannabis parallels the climates that gave rise to the tobacco and prescription opioid epidemics, suggesting that continued omission may result in negative public health consequences. However, translating methodological framework developed through research on these compounds may promote rapid advances in cannabis science germane to regulatory knowledge gaps. The present review highlights specific advancements in these areas, as well as in alcohol regulation, that are prime for informing policy-relevant cannabis science, and also offers some recommendations for evidence-based regulatory policy. Resulting progress may directly inform both regulation of cannabis in both medical and licit recreational drug frameworks, and new cannabis-related public health initiatives.
登录
查看更多内容
影响因子：
5.6
作者：
Crippa, Jose A. S.;Crippa, Ana C. S.;Zuardi, Antonio W.
通讯作者：
Zuardi, Antonio W.
影响因子：
7.6
作者：
Cooper, Ziva D.;Bedi, Gillinder;Haney, Margaret
通讯作者：
Haney, Margaret
CDC规定慢性疼痛的阿片类药物的指南 - 美国，2016年。
DOI：
10.1001/jama.2016.1464
发表时间：
2016-04-19
期刊：
JAMA
影响因子：
--
作者：
Dowell D;Haegerich TM;Chou R
通讯作者：
Chou R
影响因子：
3.8
作者：
Casswell, S;Maxwell, A
通讯作者：
Maxwell, A
影响因子：
2.8
作者：
Anderson, Peter;de Bruijn, Avalon;Hastings, Gerard
通讯作者：
Hastings, Gerard